Novartis (NOVOB DC) discontinued development of vhb937 in amyotrophic lateral sclerosis (ALS) following results from the phase 2 Astrals study; vhb937 did not meet its primary or secondary endpoints

A clean phase 2 miss with both primary and secondary endpoints failed is the more definitive variety of pipeline discontinuation, and in large-cap pharma such terminations in neurology have historically been absorbed without lasting damage to the equity, since single early-stage assets rarely carry material value in sum-of-the-parts models for diversified names. ALS specifically has a long record of failed late preclinical and mid-stage programmes across the industry, a pattern that has conditioned muted reactions and kept expectations for any novel mechanism in the indication low. The read-through channel is to peers working adjacent mechanisms or the same target biology rather than to the parent, and to any partner or originator of the asset if it was in-licensed, where milestone and royalty assumptions unwind. Worth noting is whether discontinuation triggers pipeline reprioritisation language at the next capital markets communication, as clustered neuroscience exits have at times signalled broader strategic retrenchment. The follow-ons are the usual ones: updated pipeline disclosures, any write-down commentary, and data presentations clarifying whether the failure was mechanism-specific or execution-related.